<DOC>
	<DOCNO>NCT00696163</DOCNO>
	<brief_summary>This study conduct Asia . The aim observational study evaluate quality life clinical outcome subject use NovoMix® 30 ( biphasic insulin aspart 30 ) treatment diabetes mellitus normal clinical practice condition India .</brief_summary>
	<brief_title>Observational Study Assess Quality Life Clinical Outcomes Subjects Using NovoMix® 30 Treatment Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes , include newlydiagnosed never receive insulin insulin analogue , discretion physician . Currently treat NovoMix® 30 Subjects unlikely comply protocol requirement Previously enrol study Hypersensitivity biphasic insulin aspart excipients Women pregnant , breast feeding intention become pregnant within next 12 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>